Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. - Wikidata - wikimedia - TriplyDB

Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

http://www.wikidata.org/entity/Q34128868

about

Phosphodiesterases and cardiac cGMP: evolving roles and controversies Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling.Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts.Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95 Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.Sildenafil exposure and hemodynamic effect after Fontan surgery Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.Phosphodiesterases and cyclic GMP regulation in heart muscle.Mechanisms and management of doxorubicin cardiotoxicity.Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line.Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation.Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation.Cell signaling pathways for the regulation of GATA4 transcription factor: Implications for cell growth and apoptosis.Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms.Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats.Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.Phosphodiesterase type 5 and cancers: progress and challenges.Effects of phosphodiestrase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression.The environmental pollutant BDE-209 regulates NO/cGMP signaling through activation of NMDA receptors in neurons.Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers

P2860

Q27692588-F7A1CA73-2DA2-4FEE-8D95-FDAD40417EF0 Q28084015-466D8938-D88A-4135-A7BF-851ABAADE8C9 Q28534483-80F7C188-D33E-4C08-865A-61A9039F6AEB Q28551385-4A54E981-5157-49CF-8F3B-7BF491CA89CA Q33701938-E9D492CB-B5DF-4A9D-9ADE-6C5336F64283 Q33798502-AB84929A-8202-43AB-A015-E297A349CF9F Q34152435-A4FAEF4F-A570-44FF-B15E-EFBEF6563691 Q34277031-9B857A4D-32FD-40BB-B54A-23A78075C933 Q34428464-773A734A-0043-4B86-84C0-1DA385BAF8DA Q34793299-699257ED-A316-4E4C-B7BC-5D8722EA4F4B Q35500693-9C5D739C-B0CB-4415-B735-DC3991677EA4 Q35827798-3BF5C869-303B-404B-B295-522E7599287F Q36022217-D45FB44B-9E7C-4530-992D-359D8AB97F49 Q36128551-D1DCE357-6338-4462-AF7B-21BC87075B4C Q36782452-EF44B4DC-0558-4672-9D06-93A715A67417 Q37075920-5F114D13-981C-4C21-833C-463D4B2FD8DB Q37460315-3AF0E498-8D19-45C1-948C-D2D58C618C5F Q37613120-448DD087-7BD7-4B40-8B04-50F7DA06CAD5 Q37929740-938B696F-5B4B-4926-903D-951A6DD2D0D9 Q37937579-28181317-F629-4A01-8B5A-B853AE9CED4A Q38033089-DEF92801-2B6A-4D57-A36D-B074C4972A4E Q38473474-914522F3-7F8C-4329-9543-F1CDF76DEAD6 Q38800300-4957F121-8A9E-453B-9862-C81C9EB286AD Q39141728-91CA0CD0-2E8D-4B41-B498-73927E662A3F Q39172875-75CAFB4C-43EA-4788-A7B7-A47FE5C3ED9F Q41045943-1ADEA781-D4C2-49CC-8532-0B5479495F44 Q42646273-FA97DE0C-8FA8-47AB-A1EE-EEE6215388A2 Q42718368-49400C5D-4196-44EB-8D4C-7113C8010FBC Q44970917-D310CB19-4999-43AF-B287-3B51249570BC Q45053546-E02D869B-380F-40C6-8EB3-E456B103C14C Q45993830-CFE8A02B-FB16-4EF3-AD3D-01DAF0B5982C Q46753476-D1746025-00BB-4289-A06A-C5CB48970C62 Q47115167-A9215CBD-2B3A-4A8C-91D7-ABFAF73EAE7D Q47171803-AF4711E8-61F2-40F3-8EAF-F786C38BE9C9 Q49892684-18B88D76-9B5B-4430-909F-A5141D247F61 Q49904989-2EC9A91E-0822-44BF-B097-44FCE92D54B2 Q50906948-3FFB18D4-D5BF-417E-82B8-3C79119412DD Q51760757-26A63AA1-EB82-4B22-B2DC-B2599919D774 Q58693257-85B1CA35-BEA8-4A39-8685-AAEF4F59547F

P2860

Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

http://www.wikidata.org/entity/Q34128868

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@ast

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@en

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@nl

type

label

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@ast

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@en

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@nl

prefLabel

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@ast

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@en

Long-acting phosphodiesterase- ...... with chemotherapeutic effect.

@nl

P1433

Q34128868-171D638F-5C87-4792-8A7E-FD186A5BAB6C

P1476

Q34128868-C157AF4A-0D27-46FC-91BE-BC6C786F4DDA

P2093

Q34128868-28D55CCF-1209-4130-A786-EB4FC038EDB8

Q34128868-5F372AFB-2CF6-4427-8B8F-98479CBCEE63

Q34128868-84D51665-7442-429B-8AB9-FB67C3DE7571

Q34128868-FBF38730-89A9-4583-84F0-58B80714C814

P2860

Q34128868-00A3A859-7369-45C1-8036-387F3D87DC12

Q34128868-070E5514-846E-4F5E-BDB9-F03DD2DEBB9A

Q34128868-10EB14D8-4563-4E7A-AB90-E49B99D4E101

Q34128868-13C7B9DD-BD52-4D25-AF13-101B0EFC4F83

Q34128868-187CEE11-6ABD-4F00-9F74-F065393120D9

Q34128868-1A26E1A6-2A2B-4FAB-9C89-42187503A28D

Q34128868-2144EF5F-9503-402B-9DAE-4F7957FAAC05

Q34128868-3402C94F-103A-451F-8C14-E0F682CCB1A6

Q34128868-3C1A4062-D9E7-4072-9894-AFCB0920BE5E

Q34128868-3F69143D-37D4-4B1B-971B-07F54A942793

P304

Q34128868-109D1FD8-BDFE-4F3B-87D5-1193C1BF0544

P31

Q34128868-6692C911-D96D-42D5-9171-CAFF60EA23DE

P356

Q34128868-4C2D8462-BB4A-4ACD-943E-278C5ADF2AB8

P407

Q34128868-B13DBDBE-EF81-4DD3-A3E4-9DD7F77839A4

P433

Q34128868-C99069BA-18A5-4FA7-9DAC-C3356FD02927

P478

Q34128868-0D0B29BA-A4B7-4C4E-BFD8-75500186EA56

P50

Q34128868-381B9BE9-3928-4186-8BCA-912A7E3C58B0

Q34128868-F6660785-CD41-490B-A704-C4C24183254C

P577

Q34128868-D6D81898-D18B-4D56-9944-89BAA0E0D59E

P5875

Q34128868-0B96ABC3-4ED0-4DD5-B4F3-40483062C1C1

P698

Q34128868-FBF5530C-5089-45BB-9B0A-7C27938A8734

P921

Q34128868-BD771E99-A662-44DE-9A34-D4C6F6D7B64F

P932

Q34128868-105E9C70-EDDC-4C79-A403-57B4BC12133E

P356

JPET.110.170191

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Long-acting phosphodiesterase- ...... g with chemotherapeutic effect

@en

P2093

David Durrant

http://www.w3.org/2001/XMLSchema#string

Rakesh C Kukreja

http://www.w3.org/2001/XMLSchema#string

Saisudha Koka

http://www.w3.org/2001/XMLSchema#string

Shu-Guang Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Anthracycline cardiomyopathy monitored by morphologic changes

Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity.

Adriamycin-induced heart failure: mechanism and modulation.

Phosphodiesterase 5 inhibitors: current status and potential applications.

A clinicopathologic analysis of adriamycin cardiotoxicity.

Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide

Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction.

Tadalafil pharmacokinetics in healthy subjects

P304

1023-1030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.110.170191

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

334

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44668455

http://www.w3.org/2001/XMLSchema#string

P698

20543097

http://www.w3.org/2001/XMLSchema#string

P921

P932

2939673

http://www.w3.org/2001/XMLSchema#string